ENTO
Price
$5.09
Change
+$0.10 (+2.00%)
Updated
Sep 23 closing price
Capitalization
8.09M
GLABF
Price
$0.41
Change
-$0.00 (-0.00%)
Updated
Sep 22 closing price
Capitalization
27.77M
Interact to see
Advertisement

ENTO vs GLABF

Header iconENTO vs GLABF Comparison
Open Charts ENTO vs GLABFBanner chart's image
Entero Therapeutics
Price$5.09
Change+$0.10 (+2.00%)
Volume$62.09K
Capitalization8.09M
GEMINA LABORATORIES
Price$0.41
Change-$0.00 (-0.00%)
Volume$1K
Capitalization27.77M
ENTO vs GLABF Comparison Chart in %
Loading...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLABF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTO vs. GLABF commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTO is a StrongBuy and GLABF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ENTO: $5.09 vs. GLABF: $0.41)
Brand notoriety: ENTO and GLABF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTO: 3% vs. GLABF: 9%
Market capitalization -- ENTO: $8.09M vs. GLABF: $27.77M
ENTO [@Biotechnology] is valued at $8.09M. GLABF’s [@Biotechnology] market capitalization is $27.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTO’s FA Score shows that 1 FA rating(s) are green whileGLABF’s FA Score has 0 green FA rating(s).

  • ENTO’s FA Score: 1 green, 4 red.
  • GLABF’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTO is a better buy in the long-term than GLABF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTO’s TA Score shows that 4 TA indicator(s) are bullish while GLABF’s TA Score has 2 bullish TA indicator(s).

  • ENTO’s TA Score: 4 bullish, 4 bearish.
  • GLABF’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ENTO is a better buy in the short-term than GLABF.

Price Growth

ENTO (@Biotechnology) experienced а +25.37% price change this week, while GLABF (@Biotechnology) price change was +64.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLABF($27.8M) has a higher market cap than ENTO($8.09M). ENTO YTD gains are higher at: 172.776 vs. GLABF (-24.936). GLABF has higher annual earnings (EBITDA): -3.73M vs. ENTO (-4.66M). GLABF has more cash in the bank: 15K vs. ENTO (4.47K). GLABF has less debt than ENTO: GLABF (244K) vs ENTO (836K). GLABF has higher revenues than ENTO: GLABF (10.9K) vs ENTO (0).
ENTOGLABFENTO / GLABF
Capitalization8.09M27.8M29%
EBITDA-4.66M-3.73M125%
Gain YTD172.776-24.936-693%
P/E Ratio0.03N/A-
Revenue010.9K-
Total Cash4.47K15K30%
Total Debt836K244K343%
FUNDAMENTALS RATINGS
ENTO: Fundamental Ratings
ENTO
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
86
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTOGLABF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
53%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
40%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
38%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
60%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLABF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALPMF11.300.30
+2.73%
Astellas Pharma, Inc.
SFUNY5.50N/A
N/A
Fang Holdings Limited
FLIDY6.53N/A
N/A
FLSmidth & Co. A/S
SHANF0.56N/A
N/A
Shandong Molomg Petroleum Machinery Co., Ltd.
FLWBF0.04N/A
N/A
Flow Beverage Corp.

ENTO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTO has been loosely correlated with IVVD. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTO jumps, then IVVD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTO
1D Price
Change %
ENTO100%
+2.00%
IVVD - ENTO
65%
Loosely correlated
-4.92%
SRRK - ENTO
38%
Loosely correlated
+3.59%
RLMD - ENTO
36%
Loosely correlated
+1.21%
NEVPF - ENTO
31%
Poorly correlated
N/A
CABA - ENTO
29%
Poorly correlated
+4.76%
More

GLABF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLABF has been loosely correlated with ELVAF. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if GLABF jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLABF
1D Price
Change %
GLABF100%
N/A
ELVAF - GLABF
33%
Loosely correlated
N/A
VANI - GLABF
29%
Poorly correlated
-3.23%
WHWK - GLABF
23%
Poorly correlated
+1.05%
VKTX - GLABF
20%
Poorly correlated
-4.88%
ENTO - GLABF
8%
Poorly correlated
+2.00%
More